招银国际发表研究报告指，三生制药(01530.HK) 将PD-1/VEGF双抗(SSGJ-707)的中国以外权益授予辉瑞(PFE.US) ，将获得12.5亿美元的首付款及最高达48亿美元的里程碑付款，并将获得双位数的产品销售分成，交易规模大幅超出市场预期。公司将保留707在中国的权益，而辉瑞将拥有707在中国商业化的选择权。此外，授权交易达成后，辉瑞还将以30日成交量加权平均价认购公司1亿美元的普通股。
该行认为，有关交易的达成得益于707在临床展现的同类最佳潜力，且研发进度全球领先。借助辉瑞丰富的临床资源和强大的执行能力，707的海外临床进度可望快速追赶，并充分挖掘该分子的潜力。
该行看好707在全球的潜力，相信里程碑和销售分成将持续增加三生制药的利润，将其目标价由14.18元上调至28.32元，维持“买入”评级。(sl/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-22 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.